Skip to main content
SpringerLink
Log in
Book cover

Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias pp 231–252Cite as

Interferon therapy for lymphoproliferative disorders

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 38))

Abstract

Interferon was the term originally applied to a soluble factor that was recognized by its ability to induce interference against viral infection of chick chorio-allantoic membrane by influenza A virus [1]. It has subsequently been shown to be a family of closely related proteins and glycoproteins which, in addition to antiviral activity, are potent regulators of cellular function and structure and possess direct antiproliferative activities. These latter properties underlie the current interest in interferon as an anticancer agent.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Isaacs A, Lindenman J: Virus interference: I. The interferon. Proc R Soc Lond Biol 147:258–267, 1957.

    PubMed  CAS  Google Scholar 

  2. Stewart WE II, Blalock JE, Burke DC, et al: Interferon nomenclature. J Immunol (letters to the editor) 125:2353, 1980.

    CAS  Google Scholar 

  3. Fleischmann WR, Klimpel GR, Tyring SK, Voss WR, Baron S: Interferon and cancer: Current use and novel approaches. In: Sunkara PS (ed): Novel Approaches to Cancer Chemotherapy, Orlando, Academic Press, 1984, pp 1–22.

    Google Scholar 

  4. Sehgal PB: The interferon gene. Biochim Biophys Acta 695:17–33, 1982.

    PubMed  CAS  Google Scholar 

  5. Borden EC: Progress toward therapeutic application of interferons, 1979–1983. Cancer 54:2770–2776, 1984.

    PubMed  CAS  Google Scholar 

  6. Hawkins MJ, Borden EC, Merritt JA, et al: Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. J Clin Oncol 2:221–226, 1984.

    PubMed  CAS  Google Scholar 

  7. Cantell K, Hirvonen S: Preparation of human leukocyte interferon for clinical use. Texas Rep Biol Med 35:138–144, 1977.

    CAS  Google Scholar 

  8. Pestka S: The purification and manufacture of human interferons. Sci Am 249:37–43, 1983.

    PubMed  CAS  Google Scholar 

  9. Lin LS, Stewart WE II: Purification of human leukocyte interferon by two-dimensional Polyacrylamide gel electrophoresis. Methods Enzymol 78:481, 1981.

    PubMed  CAS  Google Scholar 

  10. Berg K, Heron I: Antibody affinity chromatography of human leukocyte interferon. Methods Enzymol 78:487, 1981.

    PubMed  CAS  Google Scholar 

  11. Epstein LB: Interferon-gamma: Success, structure and speculation. Nature 295–454, 1982.

    Google Scholar 

  12. Yip YK, Pang RH, Urban C, Vilcek J: Partial purification and characterization of human gamma (immune) interferon. Proc Natl Acad Sci USA 78:1601–1605, 1981.

    PubMed  CAS  Google Scholar 

  13. Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336–352, 1984.

    PubMed  CAS  Google Scholar 

  14. Bonnern EM, Spiegel RJ: Interferon-α: Current status and future promise. J Biol Resp Modif 3:580–598, 1984.

    Google Scholar 

  15. Auerbuch SD, Austin HA, Sherwin SA, et al: Acute interstitial nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 301:32–5, 1984.

    Google Scholar 

  16. Sherwin SA, Knost JA, Fein S, et al: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461–6, 1982.

    PubMed  CAS  Google Scholar 

  17. Golomb HM: Hairy cell leukemia: An unusual lymphoproliferative disease. A study of 24 patients. Cancer 42:946–956, 1978.

    PubMed  CAS  Google Scholar 

  18. Quesada JR, Reuben J, Manning JT, Hirsch EM, Gutterman JY: Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15–18, 1984.

    PubMed  CAS  Google Scholar 

  19. Quesada JR, Hersh EM, Gutterman JU: Treatment of hairy cell leukemia with alpha interferon (abstract). Proc Am Soc Clin Oncol 3:207, 1984.

    Google Scholar 

  20. Quesada JR, Hersh EM, Manning JT, et al: Treatment of hairy cell leukemia with recombinant α-interferon. Blood 68:493–497, 1986.

    PubMed  CAS  Google Scholar 

  21. Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K: Treatment of hairy cell leukemia with recombinant alpha2 interferon. Blood 65:644–8, 1985.

    PubMed  CAS  Google Scholar 

  22. Jacobs AD, Champlin RE, Golde DW: Recombinant α-2-interferon for hairy cell leukemia. Blood 65:1017–1020, 1985.

    PubMed  CAS  Google Scholar 

  23. Thompson JA, Brady J, Kidd P, Fefer A: Recombinant α–2-interferon in the treatment of hairy cell leukemia. Cancer Treat Rep 69:791–3, 1985.

    PubMed  CAS  Google Scholar 

  24. Foon KA, Maluish AE, Abrams PG, et al: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. Am J Med 80:351–356, 1986.

    PubMed  CAS  Google Scholar 

  25. Worman CP, Catovsky D, Bevan PC, et al: Interferon is effective in hairy-cell leukemia. Br J Haem 60:759–763, 1985.

    CAS  Google Scholar 

  26. Habermann T, Hoagland H, Chang M, Phylidy R: A phase II trial of alpha recombinant interferon in hairy cell leukemia in patients with advanced disease (abstract). Blood (suppl 1) 66:2009, 1985.

    Google Scholar 

  27. Castaigne S, Sigaux F, Cantell K, et al: Interferon alpha in the treatment of hairy cell leukemia. Cancer 57:1681–1684, 1986.

    PubMed  CAS  Google Scholar 

  28. Ratain M, Golomb H, Vardiman J, et al: Durability of reponses to α–2-interferon in advanced hairy cell leukemia (abstract). Proc Am Soc Clin Oncol 5:163, 1986.

    Google Scholar 

  29. The non-Hodgkin’s lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical use. Cancer 49:2112–2135, 1982.

    Google Scholar 

  30. Merigan TC, Sikora K, Bredden JH, Levy R, Rosenberg SA: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N Engl J Med 299:1449–1453, 1978.

    PubMed  CAS  Google Scholar 

  31. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenbery SA, Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphomas. Blood 58:712–718, 1981.

    PubMed  CAS  Google Scholar 

  32. Foon KA, Sherwin SA, Abrams PG: Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148–1152, 1984.

    PubMed  CAS  Google Scholar 

  33. O’Connell MJ, Colgan JP, Oken MM, Ritts RE, Kay NE, Itri LM: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. J Clin Oncol 4:128–136, 1986.

    PubMed  Google Scholar 

  34. Horning SJ, Merigan TC, Krown SE, et al: Human interferon alpha in malignant lymphoma and Hodgkin’s disease. Cancer 56:1305–1310, 1985.

    PubMed  CAS  Google Scholar 

  35. Leavitt RD, Kaplan R, Ozer H: Low dose alpha-3 interferon treatment for low grade non-Hodgkin’s lymphoma (abstract). Blood (Supplement I) 64:182a, 1984.

    Google Scholar 

  36. Gutterman JU, Blumenschein GR, Alexanian R: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399–406, 1980.

    PubMed  CAS  Google Scholar 

  37. Leavitt RD, Ratanatharathorn V, Ozer H, Rudnick S, Ferraresi R: A phase II study of recombinant alpha 2 interferon in patients with malignant lymphoma with unfavorable histology (abstract). Proc Am Soc Clin Oncol 2:54, 1983.

    Google Scholar 

  38. Bunn PA, Foon KA, Ihde DC: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. An Intern Med 101:484–7, 1984.

    Google Scholar 

  39. Bunn PA, Idhe DC, Foon, KA: The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer, 57:1689–1695, 1986.

    PubMed  Google Scholar 

  40. Gale RP, Foon KA: Chronic lymphocytic leukemia, recent advances in biology and treatment. Ann Intern Med 103:101–120, 1985.

    PubMed  CAS  Google Scholar 

  41. Misset JL, Mythe G, Gastiaburu J, et al: Treatment of leukemias and lymphomas by interferons: Phase II trial of chronic lymphoid leukemia by human interferon alpha. Biomed Pharmacother 36:112–6, 1982.

    PubMed  CAS  Google Scholar 

  42. Huang A, Laszlo J, Brenckman W: Lymphoblastoid interferon (wellferon) trial in chronic lymphocytic leukemia. Proc Am Assoc Cancer Res 23:113, 1982.

    CAS  Google Scholar 

  43. Foon KA, Bottino G, Abrams PG: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 78:216–220, 1985.

    PubMed  CAS  Google Scholar 

  44. Ozer H, Leavit R, Ratanatharathorn V: Experience in the use of DNA alpha-2 interferon in the treatment of malignant lymphoma (abstract). Am Soc Hematol 62:211a, 1983.

    Google Scholar 

  45. Schulof RS, Lloyd MI, Stallings JJ, et al: Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: In vivo effects on autologous antitumor immunity. J Biol Response Mod 4:310–323, 1985.

    PubMed  CAS  Google Scholar 

  46. Bergsagel D: Plasma cell myeloma. In: Williams W, Beutler E, Ersleu A, Lichtman M (eds): Hematology, New York, McGraw Hill, 1983, pp 1078–1099.

    Google Scholar 

  47. Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H: Interferon therapy in myelomatosis. Lancet 1:245–8, 1979.

    PubMed  CAS  Google Scholar 

  48. Bjorkholm M: Daily low dose interferon versus intermittent high dose melphalan/ prednisone treatment in multiple myeloma (abstract). Proc Am Soc Clin Oncol 2:242, 1983.

    Google Scholar 

  49. Osserman EF, Sherman WH, Alexanian R, Gutterman J: Preliminary results of the American Cancer Society (ACS) sponsored trial of human leukocyte interferon (IF) in multiple myeloma (MM) (abstract). Am Assoc Can Res 21:161, 1980.

    Google Scholar 

  50. Ohno R, Kimura K: Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 57:1685–1688, 1986.

    PubMed  CAS  Google Scholar 

  51. Costanzi J, Ozer H, Scarffe H: A Phase II trial of rDNAα2-interferon in multiple myeloma. Presented at the International Symposium on Progress and Controversies in Multiple Myeloma, Padua, Italy, April 12, 1984.

    Google Scholar 

  52. Quesada JR, Alexanian R, Gutterman JU: Induction of remission and restoration of serum immunoglobulins in multiple myeloma with recombinant DNA-derived Interferon (rIFNαA) (abstract). Blood (supplement I) 64:183a, 1984.

    Google Scholar 

  53. Wagstaff J, Loynds P, Scarffe JH: Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cancer Treat Rep 69:495–498, 1985.

    PubMed  CAS  Google Scholar 

  54. Case DC, Sonneborn HL, Paul SO, et al: Phase II study of rDNA alpha-2 interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase (abstract). Blood (Suppl 1), 66:213a, 1985.

    Google Scholar 

  55. Clark RH, Dimitrov NV, Axelson JA, Charamella LJ: Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy. J Biol Resp Modif 3:613–619, 1984.

    CAS  Google Scholar 

  56. Champlin RE, Golde DW: Chronic myelogenous leukemia: Recent advances. Blood 65:1034–1047, 1985.

    Google Scholar 

  57. Talpaz M, Kantarjian H, McCredie MJ, et al: Clinical study of human alpha interferon in chronic myelogenous leukemia (abstract). Blood (Suppl 1) 66:209a, 1985.

    Google Scholar 

  58. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99:789–792, 1983.

    PubMed  CAS  Google Scholar 

  59. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065–1069, 1986.

    PubMed  CAS  Google Scholar 

  60. Velu T, Delwiche F, Flument J, Monsieur R, Stryckmans P, Wybran J: Therapy of essential thrombocythemia with human α2 recombinant interferon (abstract). Blood (Supplement 1) 64:176a, 1984.

    Google Scholar 

  61. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Hill JM: Clinical trials of human leukocyte interferon in malignancy. Texas Rep Biol Med 41:634–638, 1982.

    CAS  Google Scholar 

  62. Hill NO, Pardue A, Khan A, Aleman C, Dorn G, Hill JM: Phase I human leukocyte interferon trials in cancer and leukemia. J Clin Hem Onco 11:23–25, 1981.

    Google Scholar 

  63. Rohatiner AZ, Balkwill FR, Griffin DB, Malpas JS, Lister TA: A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmocol 9:97–102, 1982.

    CAS  Google Scholar 

  64. Rohatiner AZ, Balkwill FR, Malpas JS, Lister TA: Experience with human lymphoblastoid interferon in acute myelogenous leukemia. Cancer Chemother Pharmacol 11:56–58, 1983.

    PubMed  CAS  Google Scholar 

  65. Leavitt RD, Duffey P, Wiernik PH: A phase I/II study of recombinant leukocyte-A interferon in previously treated acute leukemia (abstract). Am Soc Hematol 62:205a, 1983.

    Google Scholar 

  66. Williams BRG: Biochemical actions of interferon. In: Sikora K (ed): Interferon and Cancer, New York, Plenum Press, 1983, pp 33–52.

    Google Scholar 

  67. Feinstein S, Traub A, Lazar A, Mizrahi A, Teitz Y: Studies on cell binding and internalization of human lymphoblastoid interferon. J IFN Res 5:65–7, 1985.

    CAS  Google Scholar 

  68. Lau AS, Hannigan GE, Freedman MH, Williams BR: Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 77:1632–1638, 1986.

    PubMed  CAS  Google Scholar 

  69. Ball LA: Induction of 2′–5′-oligoadenylate synthetase activity and a new protein by Chick interferon. Virology 94:282–296, 1979.

    PubMed  CAS  Google Scholar 

  70. Ball LA: 2′–5′-oligoadenylat synthetase, In: PD Boyer (ed): The Enzymes vol XV. New York Academic Press 1982, pp 281–313.

    Google Scholar 

  71. Merlin G, Chebath J, Benech P, Metz R, Revel M: Molecular cloning and sequence of partial cDNA for interferon-induced (2′–5′ oligo(A) synthetase mRNA from human cells. Proc Natl Acad Sci USA 80:4904–4908, 1983.

    PubMed  CAS  Google Scholar 

  72. Revel M, Kimchi A, Shulman L, et al: Role of interferon induced enzymes in the antiviral and antimitogenic effects of interferon. Ann NY Acad Sci 350:349–472, 1980.

    Google Scholar 

  73. Bischoff JR, Samuel CE: Mechanism of interferon action. J Biol Chem 260:8237–8239, 1985.

    PubMed  CAS  Google Scholar 

  74. Schattner A, Merlin G, Wallach D, et al: Monitoring of interferon therapy by assay of 2′, 5′-oligoisoadenylate synthetase in human peripheral white blood cells. J IFN Res; 1:587–594, 1981.

    CAS  Google Scholar 

  75. Merritt JA, Borden EC, Ball LA: Measurement of 2′, 5′-oligadenylate synthetase in patients receiving interferon-alpha. J IFN Res 5:191–198, 1985.

    CAS  Google Scholar 

  76. Balkwill FR, Oliver RTD: Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. Int J Cancer 20:500–505, 1977.

    PubMed  CAS  Google Scholar 

  77. Borden EC, Hogan TF, Voelkel JG: Comparative antiproliferative activity in vitro of natural interferons a and ß for diploid and transformed human cells. Cancer Res 42:4948–4953, 1982.

    PubMed  CAS  Google Scholar 

  78. Chadha KC, Srivastava BI: Comparison of the antiproliferative effects of human fibroblast and leukocyte interferons on various leukemic cell lines. J Clin Hem Onc 11:55–60, 1981.

    Google Scholar 

  79. Salmon SE, Durie BG, Young L, Liu RM, Trown P, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225, 1983.

    PubMed  CAS  Google Scholar 

  80. Denz H, Lechleitner M, Marth CH, Daxenbichler G, Gastl G, Braunsteiner H: Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J IFN Res 5:147–157, 1985.

    CAS  Google Scholar 

  81. Blalock J, Georgiades JE, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immun 49:390–394, 1980.

    CAS  Google Scholar 

  82. Horoszewicz JS, Leong SS, Carter WS: Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206:1091–1093, 1979.

    PubMed  CAS  Google Scholar 

  83. Creasey AA, Batholomew JC, Merigan TC: Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77:1471–1475, 1980.

    PubMed  CAS  Google Scholar 

  84. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y: Inhibition of growth of B-16 murine malignant melanoma by exogenous interferon. Cancer Res 40:614, 1980.

    PubMed  CAS  Google Scholar 

  85. Rossi GB, Marcheglani M, Matarese GP and Gresser I: Brief communication: Inhibitory effect of interferon on multiplication of friend leukemia cells in vivo. J Natl Cancer Inst 54:993, 1975.

    PubMed  CAS  Google Scholar 

  86. Crane JL, Glasgow LA, Kern ER, Youngner JS: Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst 3:871, 1978.

    Google Scholar 

  87. Greseer I, Tovey M: Antitumor effects of interferon. Biochem Biophys Acta 516:231–247, 1978.

    Google Scholar 

  88. Yoshitake Y, Kishida T, Esaki K, Kawamata J: Antitumor effects of interferon on transplanted tumors in congenitally athymic nude mice. Giken J 19:125–7, 1976.

    Google Scholar 

  89. Balkwill FR, Moodie EM, Freedman V, Frantes KH: Human interferon inhibits the growth of established human breast tumors in the nude mouse. Int J Cancer 30:231–235, 1982.

    PubMed  CAS  Google Scholar 

  90. Gresser I: Antitumor effects of interferon. In: Klein G, Weinhouse S (eds): Advances in Cancer Research, New York, Academic Press, 16:97–140, 1972.

    Google Scholar 

  91. Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW: Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134:2783–2789, 1985.

    PubMed  CAS  Google Scholar 

  92. Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against diseases. Science 214:24–30, 1981.

    PubMed  CAS  Google Scholar 

  93. Herberman RB, Ortaldo JR, Bonnard G: Augmentation by interferon of human natural and antibody-dependent cell mediated cytotoxicity. Nature 277:221–223, 1979.

    PubMed  CAS  Google Scholar 

  94. Herberman RB, Ortaldo JR, Rubinstein M, Pestka S: Augmentation of natural and antibody-dependent cell mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol 1:149–153, 1981.

    PubMed  CAS  Google Scholar 

  95. Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H-F, Pesta S: Effect of human recombinant interferon on cytotoxic activity of natural killer cells and monocytes. Cell Immunol 67:160–167, 1982.

    PubMed  CAS  Google Scholar 

  96. Huddleston JR, Merigan TC, Oldstone MBA: Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282:417–419, 1979.

    Google Scholar 

  97. Borden EC, Holland JF, Dao T, et al: Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med 97:1–6, 1982.

    PubMed  CAS  Google Scholar 

  98. Maluish AE, Ortaldo JR, Sherwin SA, Oldham RK, Herberman RB: Function in patients receiving natural leukocyte interferon. J Biol Resp Modif 2:418–427, 1983.

    CAS  Google Scholar 

  99. Maluish AE, Leavitt R, Sherwin SA, Oldham RK, Herberman RB: Effects of recombinant interferon-α on immune function in cancer patients. J Biol Resp Modif 2:470–81, 1983.

    CAS  Google Scholar 

  100. Edwards BS, Merritt JA, Fuhlbrigge RC, Bordon EC: Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 75:1908–1913, 1985.

    PubMed  CAS  Google Scholar 

  101. Targan S, Dorey F: Interferon activation of ‘pre-spontaneous killer’ cells (pre-sk) and alteration in kinetics of lysis of both ‘pre-sk’ and active sk cells. J Immunol 124:2157, 1980.

    PubMed  CAS  Google Scholar 

  102. Timonen T, Ortaldo JR, Herberman RB: Analysis by a single cell cytotoxicity assay of natural killer (NK) cell frequencies among human large granular lymphocytes and of the effects of interferon on their activity. J Immunol 128:2514, 1982.

    PubMed  CAS  Google Scholar 

  103. Wright SC, Bonauida B: Role of natural killer cytotoxic factors (NKCF) in the mechanism of NK cell mediated cytotoxicity. In: Herberman RB (ed): NK Cells and Other Natural Effector Cells, New York, Academic Press, pp 961–968.

    Google Scholar 

  104. Steinhauer EH, Doyle AT, Kadish AS: Human natural killer cytotoxic factor (NKCF): Role of IFN-OL J Immunol 135:294–299, 1985.

    CAS  Google Scholar 

  105. Timonen T, Ortaldo JR, Herberman RB: Characteristics of large granular lymphocytes and relationship to natural killer and killer cells. J Exp Med 153:569–582, 1981.

    PubMed  CAS  Google Scholar 

  106. Masucci MG, Sziget R, Klein E, et al: Effect of interferon-α1from E. coli on some cell functions. Science 209:1431–5, 1980.

    CAS  Google Scholar 

  107. Ortaldo JR, Pestka S, Slease RB, Rubinstein M, Herberman RB: Augmentation of human K-cell activity with interferon. Scand J Immunol 12:365–369, 1980.

    PubMed  CAS  Google Scholar 

  108. Hokland P, Berg K: Interferon enhances the antibody-dependent cellular cytotoxicity of human polymorphonuclear leukocytes. J Immunol 127:1585–8, 1981.

    PubMed  CAS  Google Scholar 

  109. Djeu JY: Regulation of cell functions by interferon. In: Zoon KC, Noguchi PO, Liu T-Y (eds): Interferon: Research, Clinical Application, and Regulatory Consideration, New York, Elsevier, 1984, pp 125–131.

    Google Scholar 

  110. Ozer H, Gavigan M, O’Malley J, et al: Immunomodulation by recombinant interferon-α2 in a phase I trial in patients with lymphoproliferative malignancies. J Biol Resp Modif 2:499–515, 1983.

    CAS  Google Scholar 

  111. Rosenstreich DL: The macrophage. In: Oppenheim JJ, Rosenstreich DL, Potter M (eds): Cell Functions in Immunity and Inflammation. New York, Elsevier, North Holland, 1981, p 127.

    Google Scholar 

  112. Sone S, Utsugi T, Shirahama T, Ishii K, Mutsuura S, Mitsumasa O: Induction by interferon-a of tumoridical activity of adherent mononuclear cells from human blood: Monocytes as responder and effector cells. J Biol Resp Modif 4:134–140, 1985.

    CAS  Google Scholar 

  113. Fertsch D, Vogel SN: Recombinant interferons increase macrophage Fc receptor capacity. J Immunol 132:2436–2439, 1984.

    PubMed  CAS  Google Scholar 

  114. Sadlik JR, Hoyer M, Leyko MA, et al: Lymphocyte supernatant-induced human monocyte tumoricidal activity: Dependence on the presence of γ-interferon. Cancer Research 45:1940–1945, 1985.

    PubMed  CAS  Google Scholar 

  115. Harfast B, Huddleston JR, Casali P, Merigan TC, Oldstone MB: Inteferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol 127:2146–2150, 1981.

    PubMed  CAS  Google Scholar 

  116. Rodriguez MA, Prinz WA, Sibbitt WL, Bankhurst AD, Williams RC: a-interferon increases immunoglobulin production in cultured human mononuclear leukocytes. J Immunol 130:1215–1219, 1983.

    PubMed  CAS  Google Scholar 

  117. Choi YS, Lim KH, Sanders FK: Effect of interferon-a on pokeweed mitogen-induced differentiation of human peripheral blood B lymphocytes. Cell Immunol 64:20–28, 1981.

    PubMed  CAS  Google Scholar 

  118. Fleisher TA, Attallah AM, Tosato O, Blaese RM, Greene WC: Inhibition of human polyclonal immunoglobulin synthesis. J Immunol 129:1099–1103, 1982.

    PubMed  CAS  Google Scholar 

  119. Braun W, Levy HB: Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med 141:769–773, 1972.

    PubMed  CAS  Google Scholar 

  120. Sonnefeld G: Effects of interferon on antibody formation. In: Vilcek J, DeMaeyer E (eds): Inteferon, Volume 2: Interferons and the Immune System, Amsterdam, 1984, Elsevier Science Publishers pp 85–99.

    Google Scholar 

  121. Heron I, Berg K, Cantell K: Regulatory effect of interferon on T-cells in vitro. J Immunol 117:1370–1373, 1976.

    PubMed  CAS  Google Scholar 

  122. Fradelizi D, Gresser I: Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med 155:1610–1622, 1982.

    PubMed  CAS  Google Scholar 

  123. Schnaper HW, Aune T, Pierce C: Suppressor T cell activation by human leukocyte interferon. J Immunol 131:2301–2306, 1983.

    PubMed  CAS  Google Scholar 

  124. Gresser I: The effect of interferon on the expression of surface antigens. In: Vilcek J, DeMaeyer E (eds): Interferons and The Immune System. Elsevier Amsterdam, Science Publishers, 1984, pp 113–132.

    Google Scholar 

  125. Heron I, Hokland M, Berg K: Enhanced expression of B2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci 75:6215, 1978.

    PubMed  CAS  Google Scholar 

  126. Kelley VE, Fier W, Strom TB: Cloned human interferon-γ, but not interferon-β or α, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 132:240, 1984.

    PubMed  CAS  Google Scholar 

  127. Wallach D: The HLA proteins and a related protein of 28 KdA are preferentially induced by interferon-γ in human WISH cells; Eur J Immunol 13:794, 1983.

    PubMed  CAS  Google Scholar 

  128. Meur SC, Schlossman SF, Reinherz EL: Clonal analysis of human cytotoxic T-lympho-cytes T-4+ and T-8+ effector T-cells recognize products of different major histocompat-ability complex regions. Proc Natl Acad Sci USA 79:4395, 1982.

    Google Scholar 

  129. Erikson RL, Purchio AF, Erikson E, Collet MS, Brugge JS: Molecular events in cells transformed by Rous sacrcoma virus. J Cell Biol 87:319–325, 1980.

    PubMed  CAS  Google Scholar 

  130. Lin SL, Garber EA, Wang E, et al: Reduced synthesis of pp 60 and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol 3:1656–1664, 1983.

    PubMed  CAS  Google Scholar 

  131. Dani CH, Mechti N, Piechaczyk M, Lebleu B, Jeanteur PH, Blanchard JM: Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. Proc Natl Acad Sci, 82:4891–4899, 1985.

    Google Scholar 

  132. Strayer DR, Gillespie DH, Bressuer J, Brodsky I: Oncogene expression decreased in two patients treated with interferons (abstract). Blood (supplement I) 64:175a, 1984.

    Google Scholar 

  133. Semenzato G, Pizzolo G, Agostini C, et al: α-interferon activates the natural killer system in patients with hairy cell leukemia. Blood 68:293–296, 1986.

    PubMed  CAS  Google Scholar 

  134. Faltynek CR, Princier GL, Rusetti FW, Maluish AE, Abrams PG, Foon KA: Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 67:1077–1082, 1986.

    PubMed  CAS  Google Scholar 

  135. Samuels BL, Brownstein BH, Golomb HM: Effect of interferons on patterns of protein synthesis in hairy cells (abstract). Proc Am Assoc Can Res 26:20, 1985.

    Google Scholar 

  136. Baldini L, Cortelezzi A, Polli N, et al: Human recombinant interferon α–2C enhances the expression of class II HLA antigens on hairy cells. Blood 67:458–464, 1986.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mark S. Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul A. Bunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth A. Foon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Rochester Cancer Center, Rochester, New York, 14642, USA

    John M. Bennett

  2. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, 48109, USA

    Kenneth A. Foon

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Kluwer Academic Publishers

About this chapter

Cite this chapter

Roth, M.S., Bunn, P.A., Foon, K.A. (1988). Interferon therapy for lymphoproliferative disorders. In: Bennett, J.M., Foon, K.A. (eds) Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias. Cancer Treatment and Research, vol 38. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1713-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1713-5_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8965-4

  • Online ISBN: 978-1-4613-1713-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation